Corey J. Langer, M.D.

faculty photo
Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-206
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-615-5121
Fax: 215-615-5122
Lab: CP 215-806-6152
Education:
B.A./M.D. (Liberal Arts and Medicine 6 year Combined)
Boston University, 1981.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Maturing role of immunotherapy in advanced NSCLC.
Role of targeted agents in oncogene-driven NSCLC
New strategies in SCLC
Unique combined modality strategies integrating radiation and systemic treatment in LA-NSCLC and limited stage SCLC
Underserved populations, including older patients and those with compromised performance status.
Novel therapeutic venues in thoracic and head and neck cancer

Description of Clinical Expertise

Thoracic Medical Oncology with focus on NSCLC, SCLC, and Mesothelioma

Selected Publications

Borghaei H, Langer CJ, Paz-Ares L, Rodríguez-Abreu D, Halmos B, Garassino MC, Houghton B, Kurata T, Cheng Y, Lin J, Pietanza MC, Piperdi B, Gadgeel SM. : Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Cancer. 2020 Nov 15;126(22):4867-4877 15;126(22): 4867-4877, November 2020.

Sun L, Davis CW, Hwang WT, Jeffries S, Sulyok LF, Marmarelis ME, Singh AP, Berman AT, Feigenberg SJ, Levin W, Ciunci CA, Bauml JM, Cohen RB, Langer CJ, Aggarwal C.: Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy. Clin Lung Cancer. 2020 Nov 11:S1525-7304(20)30327-2 11(S1525-7304), November 2020.

Thompson JC, Davis C, Deshpande C, Hwang WT, Jeffries S, Huang A, Mitchell TC, Langer CJ, Albelda SM.: Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma. J Immunother Cancer. 2020 Oct;8(2):e000974. 8(2), October 2020.

Awad MM, Gadgeel SM, Borghaei H, Patnaik A, Yang JC, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Altan M, Jalal SI, Panwalkar A, Gubens M, Sequist LV, Saraf S, Zhao B, Piperdi B, Langer CJ.: Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. J Thorac Oncol. 2020 Oct 15:S1556-0864(20)30761-9 15(S1556-0864): 30761-9, October 2020.

Marmarelis ME, Langer CJ: Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations. Clin Lung Cancer. 2020 Sep;21(5):395-406 21(5): 395-406, September; Epub 2020 Jan 27 2020.

Jahanzeb M, Lin HM, Pan X, Yin Y, Baumann P, Langer CJ.: Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 Sep 18:S1525-7304(20)30268-0 18(S1525-7304), September 2020.

Singh AP, Berman AT, Marmarelis ME, Haas AR, Feigenberg SJ, Braun J, Ciunci CA, Bauml JM, Cohen RB, Kucharczuk JC, Shulman LN, Langer CJ, Aggarwal C.: Management of Lung Cancer During the COVID-19 Pandemic. JCO Oncol Pract 16(9): 579-586, September, Epub May 26, 2020 2020.

Jabbour SK, Berman AT, Decker RH, Lin Y, Feigenberg SJ, Gettinger SN, Aggarwal C, Langer CJ, Simone CB 2nd, Bradley JD, Aisner J, Malhotra J. : Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial. JAMA Oncol. 2020 Jun 1;6(6):848-855 1;6(6): 848-855, June 2020.

Aggarwal C, Thompson JC, Chien AL, Quinn KJ, Hwang WT, Black TA, Yee SS, Christensen TE, LaRiviere MJ, Silva BA, Banks KC, Nagy RJ, Helman E, Berman AT, Ciunci CA, Singh AP, Wasser JS, Bauml JM, Langer CJ, Cohen RB, Carpenter EL.: Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 May 15;26(10):2354-2361 15;26(10): 2354-2361, May; Epub 2020 Feb 26 2020.

Huber RM, Hansen KH, Paz-Ares Rodríguez L, West HL, Reckamp KL, Leighl NB, Tiseo M, Smit EF, Kim DW, Gettinger SN, Hochmair MJ, Kim SW, Langer CJ, Ahn MJ, Kim ES, Kerstein D, Groen HJM, Camidge DR.: Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. J Thorac Oncol. 15(3): 404-415, March 2020.

back to top
Last updated: 12/18/2020
The Trustees of the University of Pennsylvania